Showing 5411-5420 of 8887 results for "".
- Positive Clinical Data Show Potential of STP705 for Focal Fat Reductionhttps://practicaldermatology.com/news/sirnaomics-presents-positive-clinical-data-of-stp705-for-focal-fat-reduction/2462111/New data for the investigative STP705 injectible for focal fat reduction (FFR) are "encouraging," according to the manufacturer, who presented at the 2023 Fall Clinical Dermatology Conference, which took place October 22–25 in Las Vegas. The safety an
- Survey: Americans with Mild-to-Moderate Acne Have Defeatist Attitudes About Treatment, Despite Self-Consciousnesshttps://practicaldermatology.com/news/sun-pharma-survey-reveals-americans-with-mild-to-moderate-acne-have-defeatist-attitudes-about-treatment-despite-self-consciousness/2462110/A new survey reveals defeatist attitudes about treatment among people with mild-to-moderate acne, despite feelings of self-consciousness. Among the 1,003 survey respondents ages 13-55, only three in 10 reported having seen a dermatologist, suggesting that many people with mild-to-moderate acne ar
- Study: Gene Expression Test IDs Best Patients for Adjuvant Radiation Therapyhttps://practicaldermatology.com/news/study-gene-expression-test-ids-best-patients-for-adjuvant-radiation-therapy/2462130/New research suggests that a 40-gene expression profile (40-GEP) test can help identify the best patients for adjuvant radiation therapy for cutaneous squamous cell carcinoma (cSCC). The study, whose results were presented at ASDS 2023, consisted of two merged validation cohorts f
- FDA Approves Cosentyx for HShttps://practicaldermatology.com/news/fda-approves-cosentyx-for-hs/2462109/The US Food and Drug Administration (FDA) has given its nod to Novartis’ Cosentyx (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. The IL-17A inhibitor is the first new biologic treatment option for HS patients in nearly a decade.</
- Study Highlights Potential Minoxidil Shortagehttps://practicaldermatology.com/news/study-highlights-potential-minoxidil-shortage/2462107/Minoxidil may be in short supply at some pharmacies, potentially jeopardizing patients’ efforts to treat hair loss, according to new research in the
- Study Validates Long-Term Safety of Delgocitinib Cream in Adults With Chronic Hand Eczemahttps://practicaldermatology.com/news/study-validates-long-term-safety-of-delgocitinib-cream-in-adults-chronic-hand-eczema/2462105/LEO Pharma’s Delgocitinib Cream was well-tolerated in adults with moderate to severe chronic hand eczema (CHE), according to results from the DELTA 3 Open-Label Extension Trial. What’s more, patients who entered the DELTA 3 trial after receiving delgocitinib cream
- Exploring the Sunscreen Paradoxhttps://practicaldermatology.com/news/exploring-the-sunscreen-paradox/2462101/Sunscreen use may provide people with a false sense of security. The so-called sunscreen paradox suggests that individuals with higher levels of sun exposure also tend to use more but not an adequate quantity of sunscreen or other sun-protection measures, providing a false sense of
- Study: Psoriasis Not Caused by Somatic Mutationshttps://practicaldermatology.com/news/study-psoriasis-not-caused-by-somatic-mutations/2462099/Psoriasis is not caused or spread by spontaneous genetic mutations in the skin, new research suggests. Researchers from the Wellcome Sanger Institute in Hinxton, U.K. and collaborators sequenced skin samples from 111 people with psoriasis. They didn’t find any mutated ge
- Experts React to FDA Approval of Cabtreo Topical Gel for Acne Vulgarishttps://practicaldermatology.com/news/fda-approves-cabtreo-topical-gel-for-acne-vulgaris/2462087/The U.S. Food and Drug Administration (FDA) has approved CABTREO (clindamycin phosphate, adapalene, and benzoyl peroxide) topical gel for the topical treatment of acne vulgaris in patients aged 12 and older. Bausch Health and Ortho Dermatologics' CABTREO is the first and
- Allergan Reports Positive Topline Results From Studies of TrenibotulinumtoxinE for Glabellar Lineshttps://practicaldermatology.com/news/allergan-reports-positive-topline-results-from-studies-of-trenibotulinumtoxine-for-glabellar-lines/2462093/Allergan Aesthetics’ trenibotulinumtoxinE (BoNT/E) performed well for the treatment of moderate to severe glabellar lines, according to topline results from two pivotal Phase 3 studies. BoNT/E is a novel botulinum neurotoxin serotype E with a quick onset of action